Organization · Government VC
Extend | the National Technology Transfer Biotech Hub
Extend is a National Technology Transfer Hub in Italy, launched by CDP Venture Capital SGR in collaboration with Evotec. It focuses on translating academic biopharmaceutical research into startups and proof-of-concept projects.
Overview
What Extend | the National Technology Transfer Biotech Hub does
What Extend | the National Technology Transfer Biotech Hub is
Extend is a National Technology Transfer Hub in Italy, launched by CDP Venture Capital SGR in collaboration with Evotec. It focuses on translating academic biopharmaceutical research into startups and proof-of-concept projects.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Government VC
- Structured capabilities
- Funder
- Last reviewed
- May 6, 2026
Official channels
Find Extend | the National Technology Transfer Biotech Hub elsewhere
Open the official website or a supported primary organization account.
Capability profile
Extend | the National Technology Transfer Biotech Hub as a funder
Investment thesis
Extend aims to bridge academic biotech research to the market by identifying novel targets and therapeutic approaches, developing them through an integrated drug discovery process, and creating startups to bring science to patients.
Focus narrative
Extend invests in the biotechnology sector, particularly in therapeutic areas such as oncology, cardiovascular, respiratory, rare diseases, and central nervous system disorders. The organization supports research teams from partner universities and research centers in achieving commercially viable pre-clinical proof of concept, providing capital and technological platforms for project financing.
Value beyond capital
Extend combines financial and scientific expertise to validate research in an industrial context, offering capital and technological platforms to support the development of innovative drug discovery projects.
Terms and economics
- Typical check
- $1,600,000
- Sweet spot
- $1,600,000
Focus and fit
- Stages
- Pre-seed · Seed · Seed+
- Sectors
- Biotech & Life Sciences
- Regions
- Global
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 16
Portfolio context
Notable portfolio companies include Aptadir Therapeutics, which focuses on myelodysplastic syndromes and fragile X syndrome; Imgen-T, specializing in synthetic immunology; Novystem, developing treatments for Friedreich's ataxia; Sintica Biotech, working on therapies for melanoma; and Synaptic Brain Therapeutics, which targets epilepsy.
Common questions
What to know about Extend | the National Technology Transfer Biotech Hub
Upseed classifies Extend | the National Technology Transfer Biotech Hub under the Government VC organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 6, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.